Collaborative grant, Call number HORIZON-HLTH-2027-01-DISEASE-08
Development of innovative antimicrobials against pathogens resistant to antimicrobials
European Commission (Horizon Europe)
- , Add deadline: choose a calendar
- €8,000,000 – €10,000,000
- Early independent researcher · Mid-career researcher · Established researcher
- Institution applies
- Pharmacology, Microbiology and
About
Horizon Europe research and innovation action to advance existing therapeutic candidates, including antibody-based therapies, against one priority resistant pathogen: CRAB, carbapenem- or third-generation-cephalosporin-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, MRSA, or drug-resistant Aspergillus fumigatus or Candida. Candidates must meet a WHO innovation criterion; phage therapies are out of scope.
Topics
Eligibility
Covers: Estimated EU contribution of EUR 8–10 million per project; about five projects from a EUR 44.2 million topic budget.
Legal entities in EU Member States and Horizon Europe associated countries; other countries per Horizon Europe General Annex B.
Consortia meeting Horizon Europe eligibility; legal entities established in the United States are also eligible for Union funding under this topic. Single-stage call.
Source: ec.europa.eu